Abstract
The latest class of antiretrovirals (ARVs), including integrase strand transfer inhibitors (INSTIs), has been demonstrated to be effective for antiretroviral therapy (ART). Despite all the distinguishing characteristics of these drugs, including a high genetic barrier to resistance and lower toxicity than other ARVs, unfortunately, INSTI drug resistance mutations (DRMs) have occasionally been observed. The aim of this study was to investigate the presence of DRMs associated with INSTIs among treatment-experienced HIV-1-infected patients. From June 2012 to December 2018, a total of 655 treatment-experienced HIV-1-infected patients enrolled in this cross-sectional survey. Following amplification and sequencing of the HIV-1 integrase region of the pol gene, DRM and phylogenetic analysis were successfully carried out on the plasma samples of patients who had a viral load over 1,000 IU/ml after at least 6 months of ART. Out of the 655 patients evaluated, 62 (9.5%) had a viral load higher than 1,000 IU/ml after at least 6 months of ART. Phylogenetic analysis showed that all of the 62 HIV-1 patients experiencing treatment failure were infected with CRF35_AD, and one of these patients (1.6%) was infected with HIV-1 variants with DRMs. The DRMs that were identified belonged to the INSTI class, including E138K, G140A, S147G, and Q148R. This survey shows that DRMs belonging to the INSTI class were detected in an Iranian HIV patient who has experienced treatment failure. Therefore, regarding the presence of DRMs to INSTIs in ART-experienced patients, it seems better to perform drug resistance mutation testing in HIV patients experiencing treatment failure before changing the ART regimen and prescribing this class of medication.
Similar content being viewed by others
References
Riemenschneider M, Heider D (2016) Current approaches in computational drug resistance prediction in HIV. Curr HIV Res 14(4):307–315
Blood GAC (2016) Human immunodeficiency virus (HIV). Transfus Med Hemotherapy 43(3):203
Melhuish A, Lewthwaite P (2018) Natural history of HIV and AIDS. Medicine. 46(6):356–361
Weber IT, Harrison RW (2016) Tackling the problem of HIV drug resistance. Adv Biochem. 62:273–279
Brenner BG, Wainberg MA (2017) Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. Virus Res 239:1–9
Rossouw TM, Nieuwoudt M, Manasa J, Malherbe G, Lessells RJ, Pillay S et al (2017) HIV drug resistance levels in adults failing first-line antiretroviral therapy in an urban and a rural setting in South Africa. HIV Med 18(2):104–114
Rosemary A, Chika O, Jonathan O, Godwin I, Georgina O, Azuka O et al (2018) Genotyping performance evaluation of commercially available HIV-1 drug resistance test. PLoS One 13(6):e0198246
Michaud V, Bar-Magen T, Turgeon J, Flockhart D, Desta Z, Wainberg MA (2012) The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev 64(3):803–833
https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/21/58/fda-approved-hiv-medicines.
Tetteh RA, Yankey BA, Nartey ET, Lartey M, Leufkens HG, Dodoo AN (2017) Pre-exposure prophylaxis for HIV prevention: safety concerns. Drug saf 40(4):273–83
Clutter DS, Jordan MR, Bertagnolio S, Shafer RW (2016) HIV-1 drug resistance and resistance testing. Infect Genetics Evol 46:292–307
https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/6/drug-resistance-testing.
Jeong W, Jung IY, Choi H, Kim JH, Seong H, Ahn JY et al (2019) Integrase strand transfer inhibitor resistance mutations in antiretroviral therapy-naive and treatment-experienced HIV patients in South Korea. AIDS Res Hum Retroviruses 35(2):213–6
Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF et al (2013) Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 382(9893):700–708
Kim Y, Chin BS, Kim G, Shin HS (2018) Integrase strand transfer inhibitor resistance mutations in antiretroviral treatment-naive patients in Korea: a prospective, observational study. J Korean Med Sci 33(25):e173
Vahabpour R, Bokharaei-Salim F, Kalantari S, Garshasbi S, Monavari SH, Esghaei M et al (2017) HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals. Adv Virol 162(6):1477–1485
Manosuthi W, Ongwandee S, Bhakeecheep S, Leechawengwongs M, Ruxrungtham K, Phanuphak P et al (2015) Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand. AIDS Res Ther 12:12
Heger E, Theis AA, Remmel K, Walter H, Pironti A, Knops E et al (2016) Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors. J Virol Methods 238:29–37
Harada S, Yoshimura K, Yamaguchi A, Boonchawalit S, Yusa K, Matsushita S (2013) Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro. J Gen Virol 94(Pt 5):933–943
Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M et al (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4(3):e4724
Bradley-Stewart A, Urcia C, MacLean A, Aitken C, Gunson R (2017) HIV-1 integrase inhibitor resistance among treatment naïve patients in the West of Scotland. J Clin Virol 92:7–10
Casadellà M, Van Ham P, Noguera-Julian M, Van Kessel A, Pou C, Hofstra L et al (2015) Primary resistance to integrase strand-transfer inhibitors in Europe. J Antimicrob Chemother 70(10):2885–2888
Stekler JD, McKernan J, Milne R, Tapia KA, Mykhalchenko K, Holte S et al (2015) Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007–2013. Antiviral therapy. 20(1):77
Inzaule SC, Hamers RL, Noguera-Julian M, Casadellà M, Parera M, Rinke de Wit TF et al (2018) Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa. J Antimicrob Chemother 73(5):1167–1172
Lepik KJ, Harrigan PR, Yip B, Wang L, Robbins MA, Zhang WW et al (2017) Emergent drug resistance with integrase strand transfer inhibitor-based regimens. Aids. 31(10):1425–1434
European AIDS Clinical Society guidelines (2017). http://www.eacsociety.org/files/guidelines_8.1-english.pdf. Updated 2016. Accessed 31 May 2017 (online)
Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (2017). http://nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Updated 2016. Accessed 31 May 2017 (online)
Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN et al (2010) Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin infect Dis 50(4):605–612
Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Gatell JM, Kumar PN et al (2013) Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis 13(7):587–596
Hurt CB, Sebastian J, Hicks CB, Eron JJ (2014) Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis 58(3):423–431
Farrokhi M, Moallemi S, Baesi K, Ahsani-Nasab S, Gholami M, Sadeghi L et al (2016) HIV drug resistance and phylogeny profile in naive and antiretroviral-experienced patients in Tehran, Iran. Intervirology 59(3):131–136
Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C et al (2013) Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 381(9868):735–743
De Clercq E, Li G (2016) Approved antiviral drugs over the past 50 years. Clin Microbiol Rev 29(3):695–747
Kandel CE, Walmsley SL (2015) Dolutegravir–a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Des Dev Ther 9:3547
Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E et al (2016) Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother 60(12):7086–7097
Smith SJ, Zhao XZ, Burke TR, Hughes SH (2018) Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. 15(1):37
Oliveira M, Ibanescu R-I, Anstett K, Mésplède T, Routy J-P, Robbins MA et al (2018) Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology. 15(1):56
Gubavu C, Prazuck T, Niang M, Buret J, Mille C, Guinard J et al (2015) Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients. J Antimicrob Chemother 71(4):1046–1050
Liedtke MD, Tomlin CR, Lockhart SM, Miller MM, Rathbun RC (2014) Long-term efficacy and safety of raltegravir in the management of HIV infection. Infect Drug Resist 7:73
van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B et al (2012) Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 12(2):111–118
Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D et al (2012) Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 379(9835):2439–2448
Eron JJ Jr, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG et al (2011) Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 11(12):907–915
Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F et al (2013) Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection. N Engl J Med 369(19):1807–1818
Clotet B, Feinberg J, Van Lunzen J, Khuong-Josses M-A, Antinori A, Dumitru I et al (2014) Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 383(9936):2222–2231
Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM et al (2013) Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 13(11):927–935
Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R et al (2014) Dolutegravir in antiretroviral-experienced patients with raltegravir-and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 210(3):354–362
Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A et al (2012) Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 207(5):740–748
Ndashimye E, Avino M, Kyeyune F, Nankya I, Gibson RM, Nabulime E et al (2018) Absence of HIV-1 drug resistance mutations supports the use of dolutegravir in Uganda. AIDS Res Hum Retroviruses 34(5):404–414
Tsai H-C, Chen I-T, Wu K-S, Tseng Y-T, Sy C-L, Chen J-K et al (2018) HIV-1 integrase strand-transfer inhibitor resistance in southern Taiwan. Oncotarget. 9(38):24927
Alaoui N, El Alaoui MA, Touil N, El Annaz H, Melloul M, Tagajdid R et al (2018) Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco. BMC Res Notes 11(1):369
Rusconi S, Adorni F, Tau P, Borghi V, Pecorari M, Maserati R et al (2018) Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): durability and virological response in a large Italian HIV drug resistance network (ARCA). J Clin Virol 105:112–117
George JM, Kuriakose SS, Dee N, Stoll P, Lalani T, Dewar R et al (eds) (2018) Rapid development of high-level resistance to dolutegravir with emergence of T97A mutation in 2 treatment-experienced individuals with baseline partial sensitivity to dolutegravir. Open forum infectious diseases. Oxford University Press, Oxford
Brado D, Obasa AE, Ikomey GM, Cloete R, Singh K, Engelbrecht S et al (2018) Author Correction: Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and availability of integrase inhibitors in Cape Town, South Africa. Sci Rep 8(1):6262
Zoufaly A, Kraft C, Schmidbauer C, Puchhammer-Stoeckl E (2017) Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013. Infection 45(2):165–170
Tostevin A, White E, Dunn D, Croxford S, Delpech V, Williams I et al (2017) Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom. HIV Med 18(3):204–213
Farrokhi M, Moallemi S, Shirkoohi R, Golmohammadi R, Ahsani-Nasab S, Sardashti S et al (2017) Antiretroviral drug resistance mutations among HIV treatment failure patients in Tehran, Iran. Iran J Public Health 46(9):1256–1264
Baesi K, Moallemi S, Farrokhi M, Alinaghi SA, Truong HM (2014) Subtype classification of Iranian HIV-1 sequences registered in the HIV databases, 2006-2013. PLoS One 9(9):e105098
Golmohammadi R, Baesi K, Moradi A, Farrokhi M, McFarland W, Parsamajd S (2017) The first characterization of HIV-1 subtypes and drug resistance mutations among antiretrovirally treated patients in Kermanshah, Iran. Intervirology 60(1–2):33–37
Jahanbakhsh F, Ibe S, Hattori J, Monavari SH, Matsuda M, Maejima M et al (2013) Molecular epidemiology of HIV type 1 infection in Iran: genomic evidence of CRF35_AD predominance and CRF01_AE infection among individuals associated with injection drug use. AIDS Res Hum Retroviruses 29(1):198–203
Fox MP, Cutsem GV, Giddy J, Maskew M, Keiser O, Prozesky H et al (2012) Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr 60(4):428–437
Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, Mathee S et al (2010) Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 24(4):563–572
Joseph Davey D, Abrahams Z, Feinberg M, Prins M, Serrao C, Medeossi B et al (2018) Factors associated with recent unsuppressed viral load in HIV-1-infected patients in care on first-line antiretroviral therapy in South Africa. Int J STD AIDS 29(6):603–610
Rangarajan S, Donn JC, le Giang T, Bui DD, Hung Nguyen H, Tou PB et al (2016) Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam. J Virus Erad 2(2):94–101
Floridia M, Giuliano M, Palmisano L, Vella S (2008) Gender differences in the treatment of HIV infection. Pharmacol Res 58(3–4):173–182
Prins M, Meyer L, Hessol NA (2005) Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. AIDS. 19(4):357–370
Bastard M, Fall MB, groupe d’etude de la Cohorte A (2014) Long term adherence to HAART in Senegal. Bull de la Soc de Pathol Exotique 107(4):241–243
Bastard M, Fall MB, Laniece I, Taverne B, Desclaux A, Ecochard R et al (2011) Revisiting long-term adherence to highly active antiretroviral therapy in Senegal using latent class analysis. J Acquir Immune Defic Syndr 57(1):55–61
Shoko C, Chikobvu D (2019) A superiority of viral load over CD4 cell count when predicting mortality in HIV patients on therapy. BMC Infect Dis 19(1):169
Salazar-Vizcaya L, Keiser O, Karl T, Davies MA, Haas AD, Blaser N et al (2014) Viral load versus CD4(+) monitoring and 5-year outcomes of antiretroviral therapy in HIV-positive children in Southern Africa: a cohort-based modelling study. AIDS. 28(16):2451–2460
Brown ER, Otieno P, Mbori-Ngacha DA, Farquhar C, Obimbo EM, Nduati R et al (2009) Comparison of CD4 cell count, viral load, and other markers for the prediction of mortality among HIV-1-infected Kenyan pregnant women. J Infect Dis 199(9):1292–1300
Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL et al (2007) Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS. 21(10):1301–1308
Zhou J, Sirisanthana T, Kiertiburanakul S, Chen YM, Han N, Lim PL et al (2010) Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database. BMC Infect Dis 10:361
Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T et al (1999) Latent infection of CD4 + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5(5):512–517
Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P et al (2004) Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 364(9428):51–62
Mocroft A, Phillips AN, Ledergerber B, Smith C, Bogner JR, Lacombe K et al (2010) Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. Antivir Ther. 15(4):563–570
Iacob SA, Iacob DG, Jugulete G (2017) Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful hiv treatment-clinical points of view and practical considerations. Front Pharmacol 8:831
Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD et al (2007) Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav 11(2):185–194
Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O’Shaughnessy MV et al (2003) Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 169(7):656–661
Uthman OA, Oladimeji O, Nduka C (2017) Adherence to antiretroviral therapy among HIV-infected prisoners: a systematic review and meta-analysis. AIDS Care. 29(4):489–497
Hansana V, Sanchaisuriya P, Durham J, Sychareun V, Chaleunvong K, Boonyaleepun S et al (2013) Adherence to antiretroviral therapy (ART) among people living with HIV (PLHIV): a cross-sectional survey to measure in Lao PDR. BMC Public Health. 13:617
Gao X, Nau DP (2000) Congruence of three self-report measures of medication adherence among HIV patients. Ann Pharmacother 34(10):1117–1122
Cauldbeck MB, O’Connor C, O’Connor MB, Saunders JA, Rao B, Mallesh VG et al (2009) Adherence to anti-retroviral therapy among HIV patients in Bangalore, India. AIDS Res Ther 6:7
Acknowledgements
All authors of the present survey would like to thank all of the participants who generously enrolled.
Funding
The present research was funded by Research Deputy of IUMS, Tehran, Iran, with grant number 33002.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical approval
The present research was approved by the Iran University of Medical Sciences (IUMS) Ethical Committee (ethical code: IR.IUMS.FMD.REC 1397.083). All of the study subjects were informed about this research, and a written consent form was obtained from them.
Additional information
Handling Editor: YiMing Shao.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Marjani, A., Bokharaei-Salim, F., Jahanbakhshi, F. et al. HIV-1 integrase drug-resistance mutations in Iranian treatment-experienced HIV-1-infected patients. Arch Virol 165, 115–125 (2020). https://doi.org/10.1007/s00705-019-04463-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00705-019-04463-y